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Experimental and clinical studies have reported that testosterone has a critical role in the maintenance of homeostatic and
morphologic corpus cavernosum components, essential for normal erectile physiology. Although the exact mechanisms mediated
by testosterone in erectile function are still under investigation, recent research has suggested an important role in the regulation
of endothelial cell (EC) biological functions. Besides stimulating the production of EC mediators, testosterone is also thought
to promote the vasculogenic reendothelialization process, mediated by bone marrow-derived endothelial progenitor cells.
Additionally, testosterone seems to modulate other erectile tissue components, including trabecular smooth muscle cells, nerve
ﬁbers, and tunica albuginea structure, all essential for the erectile process. This paper summarizes current data regarding tes-
tosterone-induced cellular and molecular mechanisms that regulate penile tissue components, focusing particularly on the role of
testosterone in endothelial health and erectile function.
1.ErectileFunction:Intracellular
SignalingMechanisms
Erectile function is a complex neurovascular physiological
mechanism that depends on the interplay between central
and peripheral nervous system, vascular endothelium, and
hormonal factors, as well as, the structural integrity of the
cellular components of the penis. Erectile tissue is composed
ofsmallresistancehelicinearteriesthatemptyintosinusoidal
spaces lined by a monolayer of vascular endothelial cells
(ECs), embedded in a meshwork of interconnected smooth
muscle cells (SMCs), and extracellular matrix formed by
collagen, elastic ﬁbers, and ﬁbroblasts [1–3]. The complex
interaction of this molecular and histomorphological system
is crucial for the hemodynamic and mechanical processes
involved in normal erectile function. During erectogenesis,
a sexual stimulus results in parasympathetic nonadrenergic
noncholinergic cavernosal nerves activation, leading to the
production of neural nitric oxide (nNO) by neuronal NO
synthase (nNOS) [4]. nNO diﬀuses into adjacent SMCs
and activates the enzyme guanylyl cyclase, resulting in the
generation and intracellular increase of cycling guanosine
monophosphate (cGMP). This mediator activates multiple
signaling cascades, leading to a decrease in intracellular Ca2+
uptake, which eventuates in SMCs relaxation, cavernous
sinusoidal dilatation, and NO-mediated inﬂow of arterial
blood [5, 6]. This initial inﬂow of blood into the helicine ar-
teriesincreasesshearstress,aphenomenonthatmechanically
stimulatesendothelialNOS(eNOS)toproduceeNO,andthe
release of prostanoids and endothelium-derived hyperpolar-
izingfactors(EDHFs)[7].Theseresultintheengorgementof
sinusoidal spaces by compression of the subtunical venules,
which allows the complete occlusion of penile venous out-
ﬂow. This mechanism known as veno-occlusion allows the
maintenance of an erection. This NO/cGMP-erectile-de-
pendent mechanism is regulated by the action of phos-
phodiesterase type 5 (PDE5), an enzyme which selectively
metabolizes cGMP, resulting in the loss of arteriolar dilata-
tion and penile detumescence. Therefore, as PDE5 is critical
for the intracellular regulation of cGMP levels, this enzyme2 ISRN Endocrinology
is the target molecule for the action of PDE5 inhibitors
(PDE5I), the ﬁrst line pharmacological therapy currently
usedforthetreatmentoferectiledysfunction(ED)[8].Thus,
this complex endothelium-dependent neurovascular process
plays an important role in erection, and any functional
and/or structural alterations in corpus cavernosum (CC)
components may impair vasorelaxation and veno-occlusive
mechanisms, compromising the initiation and maintenance
of an erection, contributing to the development and progres-
sion of ED [9].
2.TheVascularEtiology of ED
ED is deﬁned as the persistent inability to achieve and/or
maintain a penile erection suﬃcient for satisfactory sexual
intercourse [10]. Although the pathophysiology of ED is
multifactorial, it has been mostly recognized as a disease
of vascular origin. Thus, the loss of functional biology and
structural integrity of penile endothelium, a condition des-
ignated as endothelial dysfunction (EDys), plays a pivotal
role in the development of ED [11]. EDys is mostly induced
by unifying processes, including alterations in the bioac-
tivity/bioavailability of eNOS/eNO and increased oxidative
stress in the penile vasculature. As result, eNOS-dependent
vasodilatationisimpairedandlatestructuralvascularabnor-
malities may occur. In addition, there are changes in antico-
agulation and anti-inﬂammatory processes, elevated leuko-
cyte adhesion, and stimulation of SMCs growth, central
mechanisms involved in both atherogenesis and ED [12].
In fact, it has been described that men with penile vascular
dysfunction have also EDys in other vascular beds. Interest-
ingly, the small diameter of the cavernosal arteries and the
high content of endothelium (compared with other organs)
suggest that the penile vasculature may be a sensitive indica-
tor of systemic vascular disease [12]. Indeed, ED is currently
considered as an early sign of subclinical EDys, occurring
prior to the manifestation of cardiovascular disease (CVD).
In fact, several vascular risk factors (VRFs), such as diabe-
tes mellitus (DM), hypertension, obesity, lipidic disorders
(a cluster of comorbidities deﬁned as Metabolic Syndrome,
MeS), and aging, are general correlates for both ED and
CVD, with EDys being the common denominator [13–
16]. Therefore, the above-mentioned VRFs are responsible
for the deregulation of several metabolic and biochemical
mechanisms involved in the disruption of endothelial func-
tionality, contributing to both penile and generalized vascu-
lopathy [16]. Additionally, the degree of EDys and vascular
injury depends on the balance between endothelial damage,
inducedbyexposuretoVRFs,andtheendogenousactivation
of repair processes. One of the mechanisms activated to
regenerate the vasculature is angiogenesis, the process by
which neighboring ECs are stimulated to proliferate and
migrate, repairing the aﬀected endothelial monolayer [17].
Furthermore, compelling studies have revealed that adult
vasculogenesis also plays a critical role in the reendothe-
lialization of damaged vasculature [18, 19]. When injuries
occur in the endothelium, bone marrow- (BM-) derived
endothelial progenitor cells (EPCs) are mobilized to the
peripheralcirculationandrecruitedtositesofvascularinsult,
where they diﬀerentiate into mature ECs integrating the
vasculature [20]. Although EPCs biological activities are still
under investigation, it has been suggested that mobiliza-
tion, recruitment, diﬀerentiation, and integration in injured
vascular sites could be impaired/aﬀected by the chronic
exposuretoVRFs[21,22].Infact,recentstudieshaveshowed
that patients with ED and CVD have reduced circulating
levels of EPCs [23, 24], establishing a link between EDys
andtheaforementionedpathologies.Indeed,recentevidence
suggested that the severity of EDys in penile tissue of patients
with VRFs correlates with the imbalance between EDys and
the impairment of endogenous repair processes, leading to
alterations in essential events involved in normal erectile
functionality [25].
3. EDysLinks Testosterone Deﬁciency,
MeS, and ED
Hypogonadism is a clinical and biochemical syndrome char-
acterized by androgen deﬁciency and low serum testosterone
levels. It can be classiﬁed as primary, testicular failure with
elevated luteinizing hormone (LH), or secondary, hypotha-
lamic-pituitary failure with decreased LH [26, 27]. Symp-
toms of hypogonadism include impaired libido, ED, diﬃ-
culty in achieving orgasm, diminished sexual penile sensa-
tion, as well as, other physical disorders including fatigue,
lack of physical strength, impaired cognitive function, and
depressed mood [28]. It is well established that hypogo-
nadism and ED are the most common disorders observed in
the aging male, a condition designated as late-onset hypog-
onadism or androgen deﬁciency in the aging male (ADAM)
[29]. In addition, a testosterone decline was also associated
with chronic medical diseases such as, MeS, DM, and CVD,
conditions with an increased morbidity and mortality [30].
Several epidemiological and interventional studies reported
aninverserelationshipbetweenendogenoustestosteroneand
increased VRFs, and overall mortality. Low testosterone lev-
els were positively associated with the presence and severity
of atherosclerosis and may contribute to increased arterial
stiﬀness and to other marked eﬀects on the cardiovascular
system (i.e., coronary heart disease, myocardial infarction,
a n ds u d d e nc a r d i a cd e a t h )[ 31–33]. Interestingly, studies
revealed that men with established CVD often have low tes-
tosterone levels, which are associated with certain degrees of
EDys, independently of the presence of other VRFs. Addi-
tionally, replacement testosterone therapy may have a bene-
ﬁcial impact by slowing the progression of CVD, and also by
preventing ED and ameliorating endothelial function, sug-
gesting a protective eﬀect of endogenous testosterone on the
endothelium [32, 34]. Furthermore, clinical and experimen-
tal observations also suggest that reduced testosterone levels
may exacerbate some of the co-morbidities associated with
the MeS. Indeed, low concentrations of testosterone in men
have been associated with type 2 DM (T2DM), visceral obe-
sity, insulin resistance, hyperinsulinemia, dyslipidemia, and
increased deposition of abdominal adipose tissue [34–36].
In addition, testosterone replacement therapy signiﬁcantly
improved lipid proﬁles, reduced body fat, lowered bloodISRN Endocrinology 3
pressure, decreased glucose levels, and improved insulin sen-
sitivity in hypogonadal men with DM [35, 37, 38]. Similarly,
correction of testosterone levels in obese men was shown to
reduce body mass index, visceral fat mass, hyperlipidemia,
andimprovedinsulinsensitivity[35,39,40].Inotherstudies,
testosterone treatment for ED ameliorated MeS components
and improved endothelial function [41, 42]. Additionally, it
was demonstrated that in hypogonadal men with ED and
venous leakage, administration of testosterone therapy alone
ameliorated erectile function by improving veno-occlusion
[43, 44]. Testosterone may have a beneﬁcial eﬀect on the
systemic vasculature, by ameliorating EDys, reinforcing the
idea that testosterone supplementation could prevent and/or
delay the progression of MeS, DM, CVD, and ED.
4.Testosterone, EndothelialHealth,
andErection
EDysisanearlyeventinthedevelopmentofvasculardiseases
that later become clinically overt. Additionally, ED is cur-
rently considered as a very early warning sign of EDys and a
silentindicatorofamoregeneralizedvascularsystemicdisor-
der. Impairment of EC structure and functionality at penile
and systemic level has been described in both experimental
andclinicalstudiesandrelatedtolowcirculatingtestosterone
levels. Studies revealed that mature ECs express androgen-
receptors, suggesting that testosterone may have a direct
genomic-mediated action through the classic activation of
nuclear androgen receptors [45]. Additionally, testosterone
may promote a nongenomic eﬀect potentially induced di-
rectly in the absence of a receptor, through a nontranscrip-
tional eﬀect, or by a distinct nonclassical receptor that is
possibly associated with the plasma membrane [46]. It was
reported that testosterone deprivation in rats, submitted to
castration or to 5α-reductase inhibitor treatment (inhibits
the conversion of testosterone to dihydrotestosterone), pro-
duced injuries in aortic ECs detected by electron microscopy
[47]. ECs ultrastructure in orchidectomized animals seemed
severely crimpled, coarse, and protuberant; with ruined cell-
cell connections, and adhesion of red blood cells to the
surface. Interestingly, administration of testosterone to these
animals showed some degree of endothelial structural recov-
ery, with few noticeable lesions detected in the monolayer
[47]. In addition, a clinical study in male outpatients who
underwent measurements of endothelial systemic function
by brachial artery ﬂow-mediated dilatation (FMD) with ul-
trasonography demonstrated that the levels of testosterone
directly correlated with the percentage of FMD [32]. This
report suggested that low plasma testosterone levels were
associated with EDys in men, independently of the presence
of other VRFs, corroborating the idea that testosterone has a
protective eﬀect in endothelial functionality [32]. At penile
level, studies in animal models suggested that testosterone
deﬁciency is associated to apoptosis of cavernosal vascular
ECs [48] and that testosterone replacement therapy was
able to induce CC cell proliferation and endothelial DNA
synthesis [49]. Additionally, testosterone has been suggested
tomodulateseveralpathwaysondiﬀerenterectiletissuecom-
ponents crucial for normal erection.
4.1. Modulation of NO and PDE5 by Testosterone. Recent
publications have attempted to describe and clarify the role
of testosterone in the regulation of molecular signaling path-
ways and cellular events in penile tissue, contributing to the
maintenance of structural homeostasis. Indeed, several clin-
ical and experimental studies revealed that deprivation/deﬁ-
ciency of testosterone may induce decrease in NO-mediated
muscle relaxation, due to a reduction in the expression/ac-
tivity of NOS; SMCs apoptosis; adipose tissue deposition
with associated ﬁbrosis of the CC; abnormal ﬁbrosis in the
tunica albuginea; impaired neural supply and disruption
of the endothelial integrity and functionality [50–52]. As
aforementioned, the critical role of the NO/cGMP signal-
ing pathway on penile vasorelaxation events and erectile
function is well documented. Compelling evidence suggests
that testosterone is involved in the regulation of corporeal
expression/activityofNOSisoforms(eNOSandnNOS),thus
maintaining an adequate NO supply. Studies performed in
orchidectomized animals demonstrated that administration
of testosterone or its metabolite 5α-dihydrotestosterone re-
stored erectile responses and NOS bioactivity, increasing NO
production in CC and penile arteries [53–55]. In addition,
molecular studies showed that penile tissue of castrated
animals has reduced nNOS mRNA transcripts compared to
control animals [56], corroborating the role of testosterone
in stimulating nNOS expression. However, it still remains
to fully elucidate the exact molecular basis underlying the
regulation of NOS by testosterone. Besides increasing NO-
mediated vasorelaxation essential for erectogenesis, testos-
terone plays also a paradoxal role in the modulation of PDE5
expression and activity. As aforesaid, PDE5 is the enzyme
responsible for catalyzing cGMP into GMP, restoring SMCs
contractility and penile ﬂaccidity. Concordantly, disrupting
PDE5 expression/bioactivity leads to alterations in normal
erectile physiology. Castration in animal models has shown
to reduce PDE5 levels/action in penile tissue. Conversely,
testosterone treatment was shown to upregulate PDE5 gene
and protein expression, as well as, the enzyme activity [57–
59]. As PDE5 is the pharmacological target for PDE5I and
its activity is reduced by hypogonadism, adequate levels of
testosterone may be necessary to improve the therapeutic
eﬃcacy of PDE5I in the management of ED. Despite the
evidence provided by studies in orchidectomized animals,
the role of testosterone in human erectile function is still
poorly understood. Clinical trials demonstrated that testos-
terone therapy in hypogonadal men with ED can increase
the number and quality of erections in 40–60% of patients
[60–62]. Nevertheless, other clinical studies demonstrated
that combination therapy with PDE5I and testosterone in
hypogonadal patients with ED signiﬁcantly improves the
ability to achieve and maintain an erection [63–65]. This
reinforces the idea that testosterone replacement therapy
should be considered for the treatment of ED in men
with low testosterone levels who have previously failed to
respond to PDE5I alone. In sum, testosterone seems to have
a dual action in the modulation of the NO/cGMP signaling
mechanism by: upregulating NOS expression (NO and con-
sequently cGMP synthesis) and modulating PDE5 activity
(cGMP degradation) in penile tissue. This may be seen as4 ISRN Endocrinology
a paradox, since testosterone upregulates erection initiation
molecules (NOS) and reduces the expression/action of PDE5
involved in penile detumescence. The testosterone-induced
balance between these enzymes may suggest a role in the
regulation of penile erection homeostatic mechanisms.
4.2.BeyondNO—TestosteroneModulatesCavernosalProteins.
It is known that vascular endothelium exerts regulatory
functions on trabecular components, via the production of
eNO and through the secretion of prostaglandins, endothe-
lin (ET), platelet-derived growth factor, and transforming
growth factor β1( T G F - β1) [66–69]. Testosterone is thought
to modulate corporeal properties by directly regulating the
production of these molecules in penile ECs. Indeed, testos-
terone was reported to decrease the synthesis and release
of the paracrine factors ET-1 and TGF-β1a n dt or e d u c e
the expression of inﬂammatory markers [50, 51]. ET-1 is
a potent vasoconstrictor secreted by ECs, which also exerts
a mitogenic eﬀect on ﬁbroblasts and on vascular SMCs,
stimulates matrix biosynthesis, and acts as a survival factor
for myoﬁbroblasts [70, 71]. Clinical studies have shown that
hypogonadal men have increased levels of circulating ET-
1, which almost decrease to normal concentrations after
testosterone replacement treatment [72]. Additionally, TGF-
β1 secreted by ECs was reported to stimulate collagen
synthesis in both CC and tunica albuginea [73, 74]. In ex-
perimental models, expression of TGF-β1 in the penis is
thought to be downregulated by the testosterone action [75].
Testosteronemayalsobedirectlyinvolvedinthereductionof
inﬂammatory markers expressed by ECs, protecting vascular
endothelial structure and function [50]. In fact, it was
reported that incubation of ECs with testosterone or 5α-
dihydrotestosteronecanpositivelyaﬀectendothelialfunction
through the reduction of the inﬂammatory response. It
was suggested that the underlying mechanisms, involved
the inhibition of tumor necrosis factor-alpha-induced acti-
vation of transcription factor-kappa B [76, 77]. Besides
testosterone-mediated eﬀects in corporeal ECs, modulating
the expression of proteins that in an autocrine and paracrine
way regulates CC function, it is also known that testosterone
may directly regulate the structure and organization of all
the other erectile tissue components. For instance, some
publications have demonstrated that testosterone modulates
the proliferation of trabecular SMCs and ﬁbroblasts. Studies
in orchidectomized animals showed that testosterone depri-
vation induces penile SMCs degeneration and apoptosis,
with a signiﬁcant increase in connective tissue deposition
[58,78,79].Concordantly,cavernosalSMCscounterpartwas
restored by testosterone replacement and erectile function
reported to improve [58, 79]. Furthermore, ultrastructural
analysis also demonstrated spatial trabecular SMCs disorga-
nization with large number of cytoplasmatic vacuoles and
decreased amount of myoﬁlaments [52, 80, 81]. Moreover,
animal models of testosterone deprivation presented penile
tissue accumulation of adipocytes, particularly in the sub-
tunical region, which may also contribute to corporeal-
occlusive dysfunction [82]. Additionally, part of the vasore-
laxation eﬀects of testosterone was reported to be mediated
through the nongenomic activation of penile SM adenosine
triphosphate-sensitiveK+ channels,inanendothelium-inde-
pendent fashion [83]. Testosterone seems also essential for
the maintenance of the tunica aluginea structure. In fact,
the tunica albuginea of castrated animals was thinner and
presented fewer elastic ﬁbers and disorganized collagen
structures [84]. These alterations may contribute to ED by
impairing tunica albuginea roles in the veno-occlusive proc-
ess. In addition, testosterone is also thought to regulate
the structure and function of penile nerve ﬁber network,
modulating the response to sexual stimulation. In fact,
experimental studies showed that testosterone deprivation
by castration altered cavernosal nerve structure and reduced
the intracavernosal pressure [85–87]. These eﬀects were
reversed by testosterone supplementation [86, 87]. Overall,
decreased testosterone seems to aﬀect all erectile tissue com-
ponents. These cellular changes, together with NO/cGMP
signaling pathway impairment, contribute to modiﬁcations
in vasorelaxation mechanisms, culminating in ED. Besides
being associated with an impairment of penile molecular
events leading to a reduced capacity of SMCs and ECs to
vasorelaxate, testosterone deﬁciency was also suggested to
aﬀect endothelial repair and reendothelialization.
4.3. Testosterone and the Vasculogenic Repair Process. It has
been reported that the degree of EDys is considered to be
the balance between endothelial injury and the endogenous
repair capacity. Reduced testosterone concentrations have
been linked to the impairment of the vasculogenic reparative
process mediated by EPCs. Recently, several studies revealed
that testosterone levels may inﬂuence the number and func-
tion of circulating EPCs, aﬀecting endothelial reendothelial-
ization. In fact, it was documented that hypogonadal men
have low number of circulating EPCs, which increase sig-
niﬁcantly after testosterone replacement therapy, suggesting
that testosterone may play a role in the mechanisms of EPCs
release from the BM [88, 89]. Since it was also reported
that EPCs express androgen receptors [90], this suggests
that testosterone may have a direct eﬀect on EPCs functions
[90, 91]. Reinforcing this hypothesis, it was reported that
testosterone may promote in vitro EPCs migration, prolif-
eration, and colony-formation, through a direct action on
androgenreceptors[89].However,themechanismsbywhich
testosterone regulates in vivo EPCs actions are still under
investigation.
5. Conclusions
Erectile function is a hemodynamic process, which involves
penile blood inﬂow and suitable veno-occlusion occurring
in an appropriate hormonal milieu. Since the penis is pre-
dominantly a vascular organ, it is established that vascular
insuﬃciency is the most common etiology present in ED
cases. Loss of EC function, a condition refereed as EDys,
plays a critical role in the development of ED and systemic
vascular disorders. Several VRFs, including the cluster of
comorbidities which compose the MeS, are key correlates
for the development of ED and generalized vasculopathy,
having EDys as the common link. Additionally, an inversedISRN Endocrinology 5
relationship between the presence VRFs and decreased
testosterone levels was reported, suggesting that testosterone
deﬁciency may be associated with EDys, ED, and CVD. In
fact, testosterone is thought to be an important mediator of
cavernosal and systemic endothelial function, by regulating
homeostatic mechanisms. More importantly, testosterone is
involved in the modulation of CC vasorelaxation events, by
regulating NOS and PDE5 expression and function. Addi-
tionally, testosterone may have direct actions in other penile
components such as SMCs, nerve ﬁbers, and tunica albug-
inea, regulating their structure and function. Furthermore,
it was described that testosterone may also stimulate the
vasculogenic repair process, promoting reendothelialization
of the VRFs-induced EC monolayer lesions, ameliorating
EDys and consequently penile and systemic vasculopathy.
Although testosterone promotes endothelial health and has
an important role in erection, further research is needed
unveil all the mechanisms by which testosterone promotes
its beneﬁcial eﬀects.
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